 Connection
Michael Wachs to Male
This is a "connection" page, showing publications Michael Wachs has written about Male.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.142 |
|
|
|
-
Chirichella TJ, Dunham CM, Zimmerman MA, Phelan EM, Mandell MS, Conzen KD, Kelley SE, Nydam TL, Bak TE, Kam I, Wachs ME. Donor preoperative oxygen delivery and post-extubation hypoxia impact donation after circulatory death hypoxic cholangiopathy. World J Gastroenterol. 2016 Mar 28; 22(12):3392-403.
Score: 0.022
-
Bauer J, Johnson S, Durham J, Ludkowski M, Trotter J, Bak T, Wachs M. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl. 2006 Oct; 12(10):1544-51.
Score: 0.012
-
Slater K, Bak TE, Kam I, Wachs ME. Living donor liver transplant for fibrolamellar hepatocellular carcinoma using a deceased donor graft to reconstruct inferior vena cava. Liver Transpl. 2004 Apr; 10(4):555-6.
Score: 0.010
-
Huang J, Yoeli D, Sundaram SS, Carpenter T, Annam A, Pahlavan S, Wachs M, Adams MA. Extracorporeal membrane oxygenation as rescue therapy in a pediatric liver transplant recipient with very severe hepatopulmonary syndrome. Pediatr Transplant. 2022 Mar; 26(2):e14185.
Score: 0.008
-
Yoeli D, Choudhury RA, Nydam TL, Pomposelli JJ, Goss JA, Pomfret EA, Wachs ME, Adams MA. The Surge in Deceased Liver Donors Due to the Opioid Epidemic: Is It Time to Split the Difference? Transplantation. 2021 10 01; 105(10):2239-2244.
Score: 0.008
-
Wachs ME, Bak TE, Karrer FM, Everson GT, Shrestha R, Trouillot TE, Mandell MS, Steinberg TG, Kam I. Adult living donor liver transplantation using a right hepatic lobe. Transplantation. 1998 Nov 27; 66(10):1313-6.
Score: 0.007
-
Kelly MA, Kaplan M, Nydam T, Wachs M, Bak T, Kam I, Zimmerman MA. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc. 2013 Nov; 45(9):3325-8.
Score: 0.005
-
Cheng SS, Berman GW, Merritt GR, Hendrickse A, Fiegel MJ, Teitelbaum I, Campsen J, Wachs M, Zimmerman M, Mandell MS. The response to methylene blue in patients with severe hypotension during liver transplantation. J Clin Anesth. 2012 Jun; 24(4):324-8.
Score: 0.004
-
Zimmerman MA, Kelly MA, Campsen J, Mandell MS, Wachs M, Bak T, Skibba A, Lancaster B, Kam I. The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clin Transplant. 2010 Jul-Aug; 24(4):E103-8.
Score: 0.004
-
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Wright F, Kam I. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008 Sep; 14(9):1281-6.
Score: 0.003
-
Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008 May; 14(5):633-8.
Score: 0.003
-
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kam I. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008 Feb; 14(2):181-5.
Score: 0.003
-
Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int. 2007 Sep; 20(9):747-53.
Score: 0.003
-
Serkova NJ, Zhang Y, Coatney JL, Hunter L, Wachs ME, Niemann CU, Mandell MS. Early detection of graft failure using the blood metabolic profile of a liver recipient. Transplantation. 2007 Feb 27; 83(4):517-21.
Score: 0.003
-
Trotter JF, Campsen J, Bak T, Wachs M, Forman L, Everson G, Kam I. Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor liver transplantation. Am J Transplant. 2006 Aug; 6(8):1882-9.
Score: 0.003
-
Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M, Trotter JF, Bak T, Wachs M, Kam I, Durham J, Everson GT. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant. 2004 May; 4(5):782-7.
Score: 0.002
-
Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, Wachs M, Bak T, Kam I, Everson GT. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl. 2004 Jan; 10(1):42-8.
Score: 0.002
-
Chonchol M, Wachs M, Taylor J, Popovtzer MM. Should we biopsy kidneys of patients post-liver transplant? Transplant Proc. 2003 Dec; 35(8):3035-8.
Score: 0.002
-
Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2003 Jul; 9(7):727-32.
Score: 0.002
-
Hayashi PH, Forman L, Steinberg T, Bak T, Wachs M, Kugelmas M, Everson GT, Kam I, Trotter JF. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl. 2003 Jul; 9(7):737-40.
Score: 0.002
-
Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 2003 May; 9(5):463-8.
Score: 0.002
-
Trotter JF, Mackenzie S, Wachs M, Bak T, Steinberg T, Polsky P, Kam I, Everson GT. Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation. Transplantation. 2003 Feb 27; 75(4):473-6.
Score: 0.002
-
Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transpl. 2002 Mar; 8(3):212-8.
Score: 0.002
-
Trotter JF, Talamantes M, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M, Everson GT, Kam I. Right hepatic lobe donation for living donor liver transplantation: impact on donor quality of life. Liver Transpl. 2001 Jun; 7(6):485-93.
Score: 0.002
-
Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl. 2001 May; 7(5):401-8.
Score: 0.002
-
Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl. 2001 Apr; 7(4):343-51.
Score: 0.002
-
Trotter JF, Bak TE, Wachs ME, Everson GT, Kam I. Combined liver-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes mellitus. Transplantation. 2000 Nov 27; 70(10):1469-71.
Score: 0.002
-
Trotter JF, Wachs M, Trouillot T, Steinberg T, Bak T, Everson GT, Kam I. Evaluation of 100 patients for living donor liver transplantation. Liver Transpl. 2000 May; 6(3):290-5.
Score: 0.002
-
Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl Surg. 1999 Sep; 5(5):375-80.
Score: 0.002
-
Ryu RK, Durham JD, Krysl J, Shrestha R, Shrestha R, Everson GT, Stephens J, Kam I, Wachs M, Kumpe DA. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J Vasc Interv Radiol. 1999 Jun; 10(6):799-805.
Score: 0.002
-
Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation. 1997 Dec 27; 64(12):1695-700.
Score: 0.002
-
Shrestha R, Durham JD, Wachs M, Bilir BM, Kam I, Trouillot T, Everson GT. Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in fulminant hepatic failure due to Budd-Chiari syndrome. Am J Gastroenterol. 1997 Dec; 92(12):2304-6.
Score: 0.002
-
Everson G, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I, Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford TP. Long-term follow-up of patients with alcoholic liver disease who underwent hepatic transplantation. Liver Transpl Surg. 1997 May; 3(3):263-74.
Score: 0.002
-
Karrer FM, Bilir B, Gill R, Ostrowska A, Stegall M, Wachs M, Kam I. Cryopreserved hepatocytes are poor stimulators of in vitro cytotoxicity. Transplant Proc. 1997 Feb-Mar; 29(1-2):1111-2.
Score: 0.001
-
Lam PW, Wachs ME, Somberg KA, Vincenti F, Lake JR, Ferrell LD. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation. 1996 Feb 15; 61(3):378-81.
Score: 0.001
-
Randall HB, Wachs ME, Somberg KA, Lake JR, Emond JC, Ascher NL, Roberts JP. The use of the T tube after orthotopic liver transplantation. Transplantation. 1996 Jan 27; 61(2):258-61.
Score: 0.001
-
Emond J, Wachs ME, Renz JF, Kelley S, Harris H, Roberts JP, Ascher NL, Lim RC. Total vascular exclusion for major hepatectomy in patients with abnormal liver parenchyma. Arch Surg. 1995 Aug; 130(8):824-30; discussion 830-1.
Score: 0.001
-
Langrehr JM, Lee KK, Wachs ME, Lee TK, Stangl MJ, Venkataramanan R, Kunz HW, Schraut WH. Comparison of the effectiveness of cyclosporine A in small-bowel transplantation using different rat strain combinations. Transplant Proc. 1990 Dec; 22(6):2533-5.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|